Valuation: ProPhase Labs, Inc.

Market Cap 127K 116K 106K 96.83K 182K 11.75M 191K 1.3M 515K 6.42M 476K 466K 20.13M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 8.65M 7.88M 7.26M 6.61M 12.4M 801M 13.03M 88.4M 35.14M 438M 32.47M 31.79M 1.37B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
87.51%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-7.28%
1 week+43.74%
Current month-9.09%
1 month-22.22%
3 months-71.66%
6 months-92.22%
Current year-98.44%
1 week 0
Extreme 0.0046
0.01
1 month 0
Extreme 0.0046
0.01
Current year 0
Extreme 0.0046
0.47
1 year 0
Extreme 0.0046
2.2
3 years 0
Extreme 0.0046
74.8
5 years 0
Extreme 0.0046
152.5
10 years 0
Extreme 0.0046
160.4
Manager TitleAgeSince
Chief Executive Officer 67 2009-06-18
Director of Finance/CFO 66 2025-08-05
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 2009-06-18
Director/Board Member 70 2009-05-31
Director/Board Member 56 2025-06-19
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/25 Free

Chief Executive Officer

500,000 1.2036%
2/17/25 Free

Chief Operating Officer

500,000 1.6737%
2/14/25 Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-7.28%+43.74%-99.63%-99.98% 127K
+1.00%-9.52%+3.60%+18.74% 103B
+3.31%-4.70%-3.14%+91.33% 99.34B
-5.70%-14.32%+18.54%+406.77% 39.64B
-0.77%-4.18%+9.46%+86.02% 31.77B
-0.47%-0.90%+38.21%+72.87% 29.81B
-0.31%-0.51%+35.05%+92.29% 28.42B
-0.15%-7.99%+37.11%+297.69% 20.95B
-1.97%-3.91%-16.30%-22.39% 19.39B
0.00%-0.38%-2.71%+33.67% 16.97B
Average -1.23%-0.19%+2.02%+97.70% 39B
Weighted average by Cap. +0.30%-6.24%+9.36%+105.30%

Financials

2024 2025
Net sales 6.77M 6.17M 5.68M 5.17M 9.7M 627M 10.19M 69.15M 27.48M 342M 25.4M 24.87M 1.07B 4.34M 3.96M 3.65M 3.32M 6.22M 402M 6.54M 44.38M 17.64M 220M 16.3M 15.96M 690M
Net income -53.36M -48.6M -44.79M -40.74M -76.43M -4.94B -80.32M -545M -217M -2.7B -200M -196M -8.47B -14.74M -13.43M -12.37M -11.25M -21.11M -1.37B -22.19M -151M -59.85M -746M -55.32M -54.15M -2.34B
Net Debt 23.9M 21.76M 20.05M 18.24M 34.22M 2.21B 35.97M 244M 97.01M 1.21B 89.65M 87.76M 3.79B 8.53M 7.77M 7.16M 6.51M 12.21M 790M 12.84M 87.11M 34.62M 431M 32M 31.32M 1.35B
Projected Income Statement - Annual - ProPhase Labs, Inc.
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
26-11-20 US$0.007000 -7.28% 12,065
26-11-19 US$0.007550 +30.17% 52,098
26-11-18 US$0.005800 -3.33% 93,054
26-11-17 US$0.006000 +20.00% 2,900
26-11-16 US$0.005000 +2.67% 283,882
  1. Stock Market
  2. Stocks
  3. PRPH Stock